Data presented at the Menopause Society Annual Meeting compared Milli expanding vaginal dilator therapy results in women over and under age 50

Materna Medical announced today that an interim menopause-focused sub-analysis from the Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study will be presented at The Menopause Society 2025 Annual Meeting.

The abstract, titled “An Interim Menopause Sub-Analysis of the POMPOM Study Evaluating the Efficacy of the Milli Expanding Dilator as a Treatment for Achieving Intercourse,” highlights promising results in women aged 50 and older using the Milli vaginal dilator, an FDA-cleared device designed to treat vaginismus and dyspareunia.

When asked to describe any impact that Milli has had on their sex life, one POMPOM participant reported, “My sex life is much better, and I really AM NOT too old! :).”

This sub-analysis compared outcomes between women over and under 50 years of age after three months of self-directed use of Milli dilation therapy. Both groups showed appreciable improvements in pain, sexual function, and progress toward achieving vaginal intercourse.

The 50+ cohort demonstrated greater improvements from their baseline in four out of six subdomains of the Female Sexual Function Index (FSFI), most notably, the satisfaction subdomain improved by 64.7% (50yo+) compared to 36.6% (<50yo).

“The findings are a crucial step forward for an often-neglected patient population,” said Dr. Sheryl Kingsberg, chief of behavioral medicine in the Department of Ob/Gyn at University Hospitals Cleveland Medical Center and a co-investigator in the POMPOM study. “Our data shows that this condition is a significant challenge for midlife and menopausal women, but it is treatable. These findings indicate that the Milli dilator is an effective, innovative tool to help our patients improve their quality of life.”

The poster will be presented during The Menopause Society 2025 Annual Meeting, taking place from October 21 to 25, 2025, at the Hyatt Regency in Orlando, FL.

For more information about the POMPOM study and the Milli expanding vaginal dilator, visit www.hellomilli.com or www.maternamedical.com.

About Us Materna Medical

Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health.

Our first product, Milli™, is a vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes have been studied in a post-market prospective virtual study named POMPOM.

Materna’s second product, Ellora™, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery in first-time moms. This product is being studied in the EASE trial, a large, randomized controlled trial in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022989212/en/